Wei Zhang

Wei Zhang

Auto-generated profile, based on publicly available information

Wei Zhang

Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
KCKun Chang
Kun Chang
YCYingji Chen
Yingji Chen
XZXuanzhi Zhang
Xuanzhi Zhang
WZWei Zhang
Wei Zhang
NXNing Xu
Ning Xu
CWChenji Wang
Chenji Wang
The KEAP1-NRF2 axis is the principal regulator of cellular responses to oxidative and electrophilic stressors. NRF2 hyperactivation is frequently observed in many types of cancer and promotes cancer initiation, progression, metastasis, and resistance to various therapies. Here, we determined that dipeptidyl peptidase 9 (DPP9) is a regulator of the KEAP1-NRF2 pathway in clear cell renal cell carcinoma (ccRCC). DPP9 was markedly overexpressed at the mRNA and protein levels in ccRCC, and high DPP9 expression levels correlated with advanced tumor stage and poor prognosis in patients with ccRCC. Protein affinity purification to identify functional partners of DPP9 revealed that it bound to KEAP1 via a conserved ESGE motif. DPP9 disrupted KEAP1-NRF2 binding by competing with NRF2 for binding to KEAP1 in an enzyme-independent manner. Upregulation of DPP9 led to stabilization of NRF2, driving NRF2-dependent transcription and thereby decreasing cellular reactive oxygen species levels. Moreover, DPP9 overexpression suppressed ferroptosis and induced resistance to sorafenib in ccRCC cells, which was largely dependent on the NRF2 transcriptional target SLC7A11. Collectively, these findings indicate that the accumulation of DPP9 results in hyperactivation of the NRF2 pathway to promote tumorigenesis and intrinsic drug resistance in ccRCC. Significance: DPP9 overcomes oxidative stress and suppresses ferroptosis in ccRCC by binding to KEAP1 and promoting NRF2 stability, which drives tumor development and sorafenib resistance.

13 December 2020 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
WZWei Zhang
Wei Zhang
XZXin Zhang
Xin Zhang
SHSheng Huang
Sheng Huang
JCJianfeng Chen
Jianfeng Chen
PDPeipei Ding
Peipei Ding
WHWeiguo Hu
Weiguo Hu
Tumor growth, especially in the late stage, requires adequate nutrients and rich vasculature, in which PKM2 plays a convergent role. It has been reported that PKM2, together with FOXM1D, is upregulated in late‐stage colorectal cancer and associated with metastasis; however, their underlying mechanism for promoting tumor progression remains elusive. Herein, we revealed that FOXM1D potentiates PKM2‐mediated glycolysis and angiogenesis through multiple protein–protein interactions. In the presence of FBP, FOXM1D binds to tetrameric PKM2 and assembles a heterooctamer, restraining PKM2 metabolic activity by about a half and thereby promoting aerobic glycolysis. Furthermore, FOXM1D interacts with PKM2 and NF‐κB and induces their nuclear translocation with the assistance of the nuclear transporter importin 4. Once in the nucleus, PKM2 and NF‐κB complexes subsequently augment VEGFA transcription. The increased VEGFA is secreted extracellularly via exosomes, an event potentiated by the interaction of FOXM1 with VPS11, eventually promoting tumor angiogenesis. Based on these findings, our study provides another insight into the role of PKM2 in the regulation of glycolysis and angiogenesis.

7 October 2022 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
LLLuying Li
Luying Li
PDPeipei Ding
Peipei Ding
XLXinyue Lv
Xinyue Lv
SXSuhong Xie
Suhong Xie
LLLing Li
Ling Li
WHWeiguo Hu
Weiguo Hu
T cell–mediated immunotherapy represents a promising strategy for cancer treatment; however, it has achieved satisfactory clinical responses in only a limited population. Thus, a broader view of the T-cell immune response is required. The Ras/MAPK pathway operates in many important signaling cascades and regulates multiple cellular activities, including T-cell development, proliferation, and function. Herein, we found that the typical membrane-bound complement regulatory protein CD59 is located intracellularly in T cells and that the intracellular form is increased in the T cells of patients with cancer. When intracellular CD59 is abundant, it facilitates Ras transport to the inner plasma membrane via direct interaction; in contrast, when CD59 is insufficient or deficient, Ras is arrested in the Golgi, thus enhancing Ras/MAPK signaling and T-cell activation, proliferation, and function. mCd59ab deficiency almost completely abolished tumor growth and metastasis in tumor-bearing mice, in which CD4+ and CD8+ T cells were significantly increased compared with their proportions in wild-type littermates, and their proportions were inversely correlated with tumor growth. Using bone marrow transplantation and CD4+ and CD8+ T-cell depletion assays, we further demonstrated the critical roles of these cells in the potent antitumor activity induced by mCd59ab deficiency. Reducing CD59 expression also enhanced MAPK signaling and T-cell activation in human T cells. Therefore, the subcellular compartmentalization of Ras regulated by intracellular CD59 provides spatial selectivity for T-cell activation and a potential T cell–mediated immunotherapeutic strategy.

28 November 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
TCTingting Cai
Tingting Cai
TFTao Feng
Tao Feng
WZWei Zhang
Wei Zhang
QGQintao Ge
Qintao Ge
LPLiangju Peng
Liangju Peng
YZYi-Ping Zhu
Yi-Ping Zhu
Background: Immune checkpoint inhibitors (ICIs) have transformed the treatment strategy for bladder cancer (BLCA), but primary resistance still occurs in most patients. Recent evidence suggests that neutrophil extracellular traps (NETs) play a key role in cancer therapy resistance, but their specific role in BLCA remains unclear. Methods: An integrated analysis of multiple clinical cohorts receiving ICIs was performed to explore the link between NETs and patient outcomes. Immunofluorescence staining, in vitro co-culture system, scanning electron microscopy, and mouse lung metastasis model were used to evaluate the biological effects of NETs. Proteomics and single-cell transcriptomics analysis were further applied to elucidate the molecular mechanisms. Results: Clinically, NETs abnormally accumulated in BLCA and promoted tumor metastasis and immunotherapy resistance in mice. Mechanistically, NETs upregulated the anti-phagocytic checkpoint STC1 in tumor cells through the TLR2-MAPK-FosL1 axis. Notably, STC1 inhibited antigen presentation by sequestering calreticulin, while its secreted form enhances NET formation, forming a self-reinforcing feedback loop. In addition, secreted STC1 impaired differentiation of CD14 + precursors into mature dendritic cells, further exacerbating immune suppression. Conclusion: This study revealed the critical role of the NETs-STC1 feedback loop in BLCA immunoresistance. Targeting this axis could simultaneously enhance efficacy and safety of immunotherapy, providing a novel translational strategy for overcoming resistance in clinical settings.

6 January 2026 in Journal of the Renin-Angiotensin-Aldosterone System
Verified
Journal Article
Open access
YHYongqiang Huang
Yongqiang Huang
WZWei Zhang
Wei Zhang
WXWenhao Xu
Wenhao Xu
LDLeilei Du
Leilei Du
XZXingming Zhang
Xingming Zhang
JWJianhua Wang
Jianhua Wang
Hypothesis/Introduction: Hypoxia defines clear cell renal cell carcinoma (ccRCC), but its transcriptional and therapeutic consequences are unclear. We hypothesized that a specific hypoxia-induced long noncoding RNA (lncRNA) signature links VHL–HIF signaling to immune modulation and anti-angiogenic therapy response. Materials and Methods: We integrated multi-cohort transcriptomic data to prioritize hypoxia-associated lncRNAs in ccRCC. Direct regulation of candidate lncRNAs by HIF-1α was validated using ChIP-qPCR, and functional assays in RCC cell lines involving HIF-1α silencing, ectopic VHL expression, and HIF-1α overexpression. The tumor microenvironment and therapeutic vulnerabilities were analyzed using bioinformatic tools. Results: We identified a five-lncRNAs signature, with AP004372.1 and AC046143.3 confirmed as direct HIF-1α transcriptional targets. This signature defined an immunosuppressive milieu with high Tregs, elevated checkpoints ( PD-1 , CTLA4 , TIGIT ), and inhibitory cytokines. These tumors also showed heightened predicted sensitivity to VEGF-targeted therapies (sunitinib, pazopanib). Conclusions: Our study uncovers a hypoxia-regulated lncRNA circuit that is directly driven by HIF-1α and functionally connected to immune evasion and angiogenic dependency. This program provides a mechanistic and clinically actionable framework for stratifying ccRCC patients beyond conventional classifiers.

11 March 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
ZXZhang Xingming
Zhang Xingming
JWJianhua Wang
Jianhua Wang
MAMierxiati Abudurexiti
Mierxiati Abudurexiti
LDLeilei Du
Leilei Du
WZWei Zhang
Wei Zhang
WWWenfeng Wang
Wenfeng Wang
Background: Prostate cancer (PCa) is widely recognized as an immunologically “cold” tumor, characterized by a paucity of effector T cells and a limited response to immune checkpoint blockade therapy. Although the chemokine receptor CXCR6 has been identified as a marker of highly cytotoxic CD8 + T cells in other malignancies, its identity, regulatory mechanisms, and clinical significance in PCa remain poorly understood. Methods: We integrated newly generated and publicly available single-cell RNA sequencing data encompassing 90 651 cells from nine patients. Multicolor immunofluorescence and flow cytometry were performed on human PCa tissue specimens stratified by Gleason Score (GS). In parallel, syngeneic mouse models, bone marrow chimeras, and in vitro T-cell functional assays were employed to investigate the role, recruitment, and transcriptional regulation of CXCR6 + CD8 + T cells. Mechanistic investigations included bulk RNA-seq, chromatin immunoprecipitation-quantitative real-time PCR, pharmacologic modulation of FOXO1, and detailed analysis of the IL-10–STAT3 signaling pathway. Results: The CXCR6 + CD8 + T cells represent a transcriptionally distinct subset with high expression of cytotoxic markers ( GZMA , GZMB , and PRF1 ), and their frequency declines significantly with increasing GS. Intratumoral maintenance of these cells is sustained by CXCL16 secreted by IL1B + M1-like macrophages; the loss of this macrophage population in advanced tumors leads to depletion of CXCR6 + CD8 + T cells. Genetic ablation of CXCR6 or depletion of CD8 + T cells accelerates tumor growth, demonstrating the essential role of CXCR6 + CD8 + T cells in antitumor immunity. At the molecular level, the FOXO1–KLF2 axis transcriptionally represses CXCR6 expression, and IL-10-mediated activation of STAT3 upregulates FOXO1 and KLF2, thereby suppressing CXCR6 expression and impairing cytotoxic function. Pharmacologic inhibition of FOXO1 enhances the expansion of CXCR6 + CD8 + T cells and acts synergistically with anti-PD-1 therapy to inhibit tumor progression. Conclusions: The CXCR6 + CD8 + T cells are critical yet progressively diminished effectors in PCa. Their persistence within the tumor microenvironment depends on CXCL16 derived from M1-like macrophages and is counteracted by IL-10-driven FOXO1–KLF2 signaling. Targeting this regulatory axis—through inhibition of FOXO1 or IL-10, for example—represents a rational therapeutic strategy to restore CXCR6 + CD8 + T-cell-mediated immunity and enhance the efficacy of immunotherapy in PCa.